TG Therapeutics | TGTX - Current Liabilities


TG Therapeutics reported $156.81M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
AbbVie USD 39.39B 376M Sep/2025
Alaunos Therapeutics USD 921K 153K Sep/2025
Amgen USD 21.79B 1.32B Sep/2025
Ardelyx USD 83.39M 1.67M Sep/2025
Arrowhead Research USD 195.49M 957K Sep/2025
Bayer EUR 28.96B 825M Sep/2025
Biogen USD 3.29B 106.3M Sep/2025
Corcept Therapeutics USD 172.26M 27.6M Sep/2025
Dynavax Technologies USD 106.84M 11.39M Sep/2025
Gilead Sciences USD 12.3B 1.11B Sep/2025
J&J USD 50.87B 3.31B Sep/2025
Novartis USD 32B 286M Sep/2025
PTC Therapeutics USD 866.24M 238.44M Sep/2025
Regeneron Pharmaceuticals USD 4.43B 758.1M Sep/2025
Roche Holding CHF 28B 421M Dec/2025
TG Therapeutics USD 156.81M 15.08M Sep/2025
Vertex Pharmaceuticals USD 4.48B 336.9M Sep/2025